Hormonal
Tirzepatide treatment for weight management produces significant weight loss (mean 22.6% over 36 weeks) accompanied by perceived improvements in appetite control, energy levels, and physical functioning, with gastrointestinal side effects being common but generally manageable.
Tirzepatide is a weekly injection approved for weight management in adults with obesity or overweight. Clinical data from the SURMOUNT-4 trial shows an average weight loss of 22.6% over 36 weeks. Patients report significant improvements in appetite control, energy, and physical functioning. Common side effects include nausea and diarrhea, which are often manageable. Most patients found the injection device easy to use and were willing to continue treatment.
During the open-label phase when all participants were taking tirzepatide, interview participants lost an average of 24.7 kg, or 22.6% of their start body weight... perceived physiological benefits included a decreased appetite (n = 78/86, 91%) and/or increased energy levels (n = 53/86, 62%).
Why this rating
Based on a large phase III trial (SURMOUNT-4) with qualitative exit interviews from 86 participants, providing robust patient-reported outcome data.
Source
Patient Experience of Treatment with Tirzepatide for Weight Management: Exit Interviews from SURMOUNT-4
Chloe Johnson et al. · Patient · 2025
DOI 10.1007/s40271-025-00730-0
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →